By a News Reporter-Staff News Editor at Drug Week -- Data detailed on Drugs and Therapies have been presented. According to news reporting originating in Columbus, Ohio, by NewsRx journalists, research stated, "Many cationic lipids have been developed for lipid-based nanoparticles (LNPs) for delivery of siRNA and microRNA (miRNA). However, less attention has been paid to 'helper lipids."
The news reporters obtained a quote from the research from Ohio State University, "Here, we investigated several 'helper lipids' and examined their effects on the physicochemical properties such as particle size and zeta potential, as well as cellular uptake and transfection efficiency. We found that inclusion of oleic acid (OA), an unsaturated fatty acid, into the LNP formulation significantly enhanced the delivery efficacy for siRNA and miRNA. For proof-of-concept, miR-122, a liver-specific microRNA associated with many liver diseases, was used as a model agent to demonstrate the hepatic delivery efficacy both in tumor cells and in animals. Compared to Lipofectamine 2000, a commercial transfection agent, LNPs containing OA delivered microRNA-122 in a more efficient manner with a 1.8-fold increase in mature miR-122 expression and a 20% decrease in Bcl-w, a target of microRNA-122. In comparison with Invivofectamine, a commercial transfection agent specifically designed for hepatic delivery, LNPs containing OA showed comparable liver accumulation and in vivo delivery efficiency. These findings demonstrated the importance of 'helper lipid' components of the LNP formulation on the cellular uptake and transfection activity of siRNA and miRNA."
According to the news reporters, the research concluded: "LNPs containing OA is a promising nanocarrier system for the delivery of RNA-based therapeutics in liver diseases."
For more information on this research see: Enhanced hepatic delivery of siRNA and microRNA using oleic acid based lipid nanoparticle formulations. Journal of Controlled Release, 2013;172(3):690-698. Journal of Controlled Release can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; Journal of Controlled Release - www.elsevier.com/wps/product/cws_home/502690)
Our news correspondents report that additional information may be obtained by contacting X.M. Wang, Ohio State University, Dept. of Pathol, Columbus, OH 43210, United States. Additional authors for this research include B. Yu, W. Ren, X.K. Mo, C.G. Zhou, H.Y. He, H.L. Jia, L. Wang, S.T. Jacob, R.J. Lee, K. Ghoshal and L.J. Lee (see also Drugs and Therapies).
Keywords for this news article include: Ohio, Columbus, United States, Drugs and Therapies, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC